Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

Table 1 Baseline demographic and clinical parameters

Characteristics	N = 70
Age	46.9 ± 1.4
Gender
Male	15 (21.4)
Female	55 (78.6)
Age at migraine onset, years	14.1 ± 0.9
Disease duration, years	33.1 ± 1.2
Concurrent oral preventive treatments	40 (57)
Monotherapy	18 (26)
Polytherapy	22 (31)
Headache days/month	21.1 ± 0.7
Previous preventive classes failure	4.7 ± 0.3
Acute medications intake/month	25 ± 3.7
Patients with MOH	64 (91.4)
Pain intensity (NRS)	8.6 ± 0.6
MIDAS	108.1 ± 11.4
HIT-6	65.9 ± 1.2
MSQ	13.2 ± 7.5
BDI-II	17.0 ± 1.5
HDRS	14.3 ± 1.2
HARS	17.1 ± 1.7
MOS sleep scale	24.7 ± 0.7
ASC-12	6.7 ± 0.7
PCS	33.2 ± 1.3
MIG-SCOG	9.9 ± 0.6

Values are mean ± standard error (SE) or number (%)
ASC-12 Allodynia Symptom Checklist-12, BDI II Beck Depression Inventory II, HARS Hamilton Anxiety Rating Scale, HDRS Hamilton Depression Rating Scale, HIT-6 headache impact test-6, MIDAS migraine disability assessment scale, MIG-SCOG MIGraine attacks - Subjective COGnitive impairments scale, MOH medication overuse headache, MOS Medical Outcomes Study, MSQ migraine-specific quality-of-life questionnaire, NRS numerical rating scale, PCS Pain Catastrophizing Scale

ISSN: 1129-2377